These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17607912)

  • 21. The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations.
    Wolf J; Dronov S; Tobin F; Goryanin I
    FEBS J; 2007 Nov; 274(21):5505-17. PubMed ID: 17916191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herpesviruses: hijacking the Ras signaling pathway.
    Filippakis H; Spandidos DA; Sourvinos G
    Biochim Biophys Acta; 2010 Jul; 1803(7):777-85. PubMed ID: 20303365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies.
    Bilanges B; Stokoe D
    Oncogene; 2007 Sep; 26(41):5973-90. PubMed ID: 17404576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered oncomodules underlie chromatin regulatory factors driver mutations.
    Frigola J; Iturbide A; Lopez-Bigas N; Peiro S; Gonzalez-Perez A
    Oncotarget; 2016 May; 7(21):30748-59. PubMed ID: 27095575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interplay among Drosophila transcription factors Ets21c, Fos and Ftz-F1 drives JNK-mediated tumor malignancy.
    Külshammer E; Mundorf J; Kilinc M; Frommolt P; Wagle P; Uhlirova M
    Dis Model Mech; 2015 Oct; 8(10):1279-93. PubMed ID: 26398940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profile associated with oncogenic ras-induced senescence, cell death, and transforming properties in human cells.
    Moumtzi SS; Roberts ML; Joyce T; Evangelidou M; Probert L; Frillingos S; Fotsis T; Pintzas A
    Cancer Invest; 2010 Jul; 28(6):563-87. PubMed ID: 19883200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for RAS mutation-tailored therapies.
    Montalvo SK; Li L; Westover KD
    Future Oncol; 2017 Feb; 13(3):263-271. PubMed ID: 27728979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What's new in ras genes? Physiological role of ras genes in signal transduction and significance of ras gene activation in tumorigenesis.
    Waldmann V; Rabes HM
    Pathol Res Pract; 1996 Sep; 192(9):883-91. PubMed ID: 8950754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
    Fang B
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
    Lv J; Wang J; Chang S; Liu M; Pang X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ras oncogenes and their downstream targets.
    Rajalingam K; Schreck R; Rapp UR; Albert S
    Biochim Biophys Acta; 2007 Aug; 1773(8):1177-95. PubMed ID: 17428555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm.
    Raimondi F; Inoue A; Kadji FMN; Shuai N; Gonzalez JC; Singh G; de la Vega AA; Sotillo R; Fischer B; Aoki J; Gutkind JS; Russell RB
    Oncogene; 2019 Sep; 38(38):6491-6506. PubMed ID: 31337866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cloning oncogenic ras-regulated genes by differential display.
    Jo H; Zhang H; Zhang R; Liang P
    Methods; 1998 Dec; 16(4):365-72. PubMed ID: 10049644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells.
    Chi S; Kitanaka C; Noguchi K; Mochizuki T; Nagashima Y; Shirouzu M; Fujita H; Yoshida M; Chen W; Asai A; Himeno M; Yokoyama S; Kuchino Y
    Oncogene; 1999 Apr; 18(13):2281-90. PubMed ID: 10327074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genomic strategy to elucidate modules of oncogenic pathway signaling networks.
    Chang JT; Carvalho C; Mori S; Bild AH; Gatza ML; Wang Q; Lucas JE; Potti A; Febbo PG; West M; Nevins JR
    Mol Cell; 2009 Apr; 34(1):104-14. PubMed ID: 19362539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.
    Zhang Z; Li M; Rayburn ER; Hill DL; Zhang R; Wang H
    Am J Pharmacogenomics; 2005; 5(4):247-57. PubMed ID: 16078861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional genomics to explore cancer cell vulnerabilities.
    Kahle KT; Kozono D; Ng K; Hsieh G; Zinn PO; Nitta M; Chen CC
    Neurosurg Focus; 2010 Jan; 28(1):E5. PubMed ID: 20043720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vertical pathway targeting in cancer therapy.
    Shahbazian D; Sznol J; Kluger HM
    Adv Pharmacol; 2012; 65():1-26. PubMed ID: 22959021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 'Pathway drug cocktail': targeting Ras signaling based on structural pathways.
    Nussinov R; Tsai CJ; Mattos C
    Trends Mol Med; 2013 Nov; 19(11):695-704. PubMed ID: 23953481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic Ras signals through activation of both phosphoinositide 3-kinase and Rac1 to induce c-Jun NH2-terminal kinase-mediated, caspase-independent cell death.
    Byun JY; Kim MJ; Yoon CH; Cha H; Yoon G; Lee SJ
    Mol Cancer Res; 2009 Sep; 7(9):1534-42. PubMed ID: 19723872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.